The Food and Drug Administration has extended by three months the review date for an experimental pill to treat HIV treatment-related diarrhea, according to Salix Pharmaceuticals, the drug's maker. FDA had been scheduled to review the drug, crofelemer, on June 5. Salix said in a statement that FDA said it needs more time for a full review, although it did not ask for any additional studies.